ArticleiScience2025
Single-cell transcriptional landscape of peripheral myeloid cells in autoimmune diseases.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- scImmuneCo: a compendium of cell-type-specific functional modules for decoding immune responses from single-cell RNA-seq data.Briefings in bioinformatics · 2026Article
- Type I Interferon-Driven Monocyte Dysregulation and MAS-associated CD8bioRxiv : the preprint server for biology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid cells are pivotal in autoimmune disorder development due to their varied immune response functions yet understanding them at the single-cell level in such conditions is limited. To address this gap, we analyzed 351,905 myeloid cells from 375 single-cell RNA sequencing samples covering 14 autoimmune diseases, which allowed us to classify myeloid cells into 13 distinct subsets with unique immunological profiles. Through pseudotime analysis, we identified a branching process leading to two intermediary inflammatory subtypes and observed dysregulation in eight co-expression modules crucial for monocyte function across autoimmune conditions. Notably, a module linked to myeloid cell activation was consistently upregulated in autoimmune disorders. This insight led us to identify potential drug targets for therapeutic repurposing within the dysregulated modules. By incorporating genetic data from genome-wide association studies, we identified 13 myeloid cell subsets predisposed to varying degrees of risk in different autoimmune conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.